NCT04952103Unknown不适用
Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
This study is a prospective, real world study.The objective is to observe the diagnosis and first-line treatment of Chinese patients with cancer of unknown primary, and collect the clinicopathological characteristics, treatment outcomes, survival and other data of the patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Had a diagnosis of cancer of unknown primary (CUP) after a standard evaluation .
- •Prepared to receive first-line therapy for CUP
排除标准
- •Patients who had previously received systemic therapy for CUP
- •Previous history of other cancers, except cervix cancer or basal cell carcinoma of the skin that has been cured
- •The investigator considered that there were contraindications to treatment or were not appropriate to participate in this study
结局指标
主要结局
Progression-free survival (PFS)
时间窗: 8 months
次要结局
未报告次要终点
研究者
Zhiguo Luo, MD, PhD
Professor
Fudan University
研究点 (1)
Loading locations...
相似试验
招募中
不适用
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.Acute Myeloid Leukemia, AdultNCT05127798Grupo Argentino de Tratamiento de la Leucemia Aguda50
招募中
不适用
RWE of 1st Line Treatment With ATO/ATRA for Adult APLPromyelocytic Leukemia, Adult AcuteNCT04897490Grupo Argentino de Tratamiento de la Leucemia Aguda50
招募中
不适用
RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALLAcute Lymphoblastic Leukemia, AdultNCT05127148Grupo Argentino de Tratamiento de la Leucemia Aguda100
已完成
不适用
Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in BrazilBreast CancerNCT05034393Latin American Cooperative Oncology Group308
已完成
不适用
Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.Stage IIIB/IVNon-Small Cell Lung CancerNCT01525199AstraZeneca450